Sequential Treatment of Hepatocellular Carcinoma by Transarterial Chemoembolization and Local Ablation or External Radiation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

57 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-04

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) can present itself in many forms (size, number of lesions) for the treatment of which a therapeutic panel can be elaborated and layered. If a curative treatment cannot be considered in case of an HCC classified in an intermediate stage, a Transcatheter Arterial Chemoembolization (TACE) can be proposed. In case of a partial response or the treatment of some lesions of a multifocal HCC, a combined treatment by stereotaxic radiotherapy (CK), radiofrequency ablation (RFA) or microwave ablation (MWA) may be initiated in accordance with a decision of the multidisciplinary consultation meeting.

The aim of this study was to evaluate the clinical outcome of HCC receiving MWA, RFA or CK after downstaging with TACE.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma

NCT02729506

Hepatocellular Carcinoma

UNKNOWN PHASE4

Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma

NCT02646137

Liver Cancer

UNKNOWN PHASE3

Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison

NCT04823715

Non-metastatic Hepatocellular Carcinoma

COMPLETED

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

NCT01850667

Hepatocellular Carcinoma

COMPLETED PHASE2

Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm

NCT01825824

Hepatocellular Carcinoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a HCC treated by TACE followed by RFA, MWA and/or CK
* from 01/2010 to 12/2020
* treated by Nancy Regional University Hospital (TACE, RFA, MWA) and Institut de Cancérologie de Lorraine (CK)

Exclusion Criteria

* Combined treatment over one year following the last TACE
* No baseline, in between or after combined treatment imaging
* Lesion appeared after TACE treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No